Q4 2022 Results
Company overview
Financial review
Innovation: Pipeline overview
2022 events¹
NME Lead
Regulatory
H1
Pluvicto™ mCRPC (US/EU ✓)
decisions
H1
VijoiceⓇ PROS (US)
H2
Scemblix 3L CML (JP/EU✓)
H2
tislelizumab ESCC 2L (US) 10
H1/H2 JakaviⓇ acute & chronic GVHD (EU
/JPx13)
H1/H2 KymriahⓇ r/r follicular lymphoma (US/EU ✓ /JP✓ )
H1/H2 BeovuⓇ DME (US/EU/JP ✓)
ensovibep COVID-19 (US)
H1/H2 Cosentyx® HS (EU/US ✓)
H1/H2 tislelizumab NSCLC (EU/US x²)
Submissions
H1
H2
tislelizumab 1L Nasopharyngeal cancer (US x2)
H2
Cosentyx Psoriatic Arthritis IV (US) 12
Submissions- H2
enabling
readouts
H2
canakinumab NSCLC Ph3 CANOPY-A (PE not met)
iptacopan PNH Ph3 APPLY-PNH✓
H2
Pluvicto™ pre-taxane mCRPC Ph3 PSMAfore³✓
2023 priorities
Appendix
Abbreviations
Innovation: Clinical trials
✓ Achieved to plan X Not achieved to plan
Other readouts
H1
sabatolimab HR-MDS Ph2 √4
H1
CosentyxⓇ Lichen planus Ph2 PRELUDE5✓ (PE not met)
H1
CosentyxⓇ axSpA IV Ph3 INVIGORATE-1 ✓
H1
icenticaftor COPD Ph2b √6
H2
UNR844 presbyopia Ph2 READER (PE not met)
Ph3/pivotal study
starts
H1
CosentyxⓇ peripheral SpA x7
H1
OAV101 SMA IT STEER ✓
H1
ensovibep COVID-19 (EMPATHY Part B) x8
H2
JDQ443 NSCLC mono
H2
ianalumab Sjögren's Syndrome ✓
H2
ianalumab Lupus Nephritis ✓
H2
ociperlimab solid tumors x
H2
PluvictoⓇ nmCRPC x11
H2
YTB323 2L DLBCL9x
H2
OAV101 SMA IT Ph3b STRENGTH ✔
PE: Primary Endpoint Note: KisqaliⓇ NATALEE Ph3 readout removed (2023 event as shared at Q1 2023). 1. Selected. 2. No US submission planned. 3. Could move to early 2023. 4. Submission will be based on Ph3 results.
5. Primary endpoint at Wk16 not met. 6. Ph2b DRF demonstrated dose response across multiple endpoints, study results presentation end 2022. Out-licensing planned. 7. Strategy update. 8. No definite start date for the IV Ph3 clinical
trial can be provided at this time. 9. Development strategy updated. 10. FDA deferred action pending completion of required inspections. 11. Ph3 in nmCRPC shifting to Ph2, with FPFV in 2023. 12. Submission included also ankylosing
spondylitis IV and non-radiographic axial SpA IV. 13. Base case approval moved to H1 2023.
50 Investor Relations | Q4 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation